Ignite Creation Date:
2025-12-26 @ 10:34 AM
Ignite Modification Date:
2025-12-31 @ 10:51 PM
Study NCT ID:
NCT01526928
Status:
TERMINATED
Last Update Posted:
2020-08-04
First Post:
2012-01-31
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients
Sponsor:
Clovis Oncology, Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Locally Advanced or Metastatic Non Small Cell Lung Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | cancer | View |
| None | metastatic | View |
| None | locally advanced | View |
| None | lung | View |
| None | non-small cell lung cancer | View |
| None | NSCLC | View |
| None | epidermal growth factor receptor | View |
| None | EGFR | View |
| None | T790M | View |
| None | CO-1686 | View |
| None | unresectable | View |
| None | recurrent | View |
| None | EGFR-directed therapy | View |
| None | irreversible EGFR inhibitor | View |
| None | TIGER | View |
| None | Rociletinib | View |